A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning

A. van Ommen-Nijhof, V. P. Retèl, M. van den Heuvel, A. Jager, W. H. van Harten, G. S. Sonke*

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)1212-1215
Number of pages4
JournalAnnals of Oncology
Volume32
Issue number10
Early online date12 Aug 2021
DOIs
Publication statusPublished - 1 Oct 2021

Bibliographical note

Funding Information:
The SONIA study is supported by ZonMw and Zorgverzekaars Nederland, grant number 848050008. The NVALT-30 Dedication trial is supported by Foundation Treatmeds, a novel foundation supported by all the large Dutch Health Insurance Companies, no grant number applicable.

Funding Information:
Pauline Evers provided input from a patient's perspective in her role as a representative of the Dutch Federation of Cancer Patient Organisations (NFK). Inge Konings provided additional input in her role as principal investigator of the SONIA study. The SONIA study is supported by ZonMw and Zorgverzekaars Nederland, grant number 848050008. The NVALT-30 Dedication trial is supported by Foundation Treatmeds, a novel foundation supported by all the large Dutch Health Insurance Companies, no grant number applicable. VPR and WHvH report a non-restricted grant from Agendia BV, which is not related to the current project. MvdH reports institutional research support from AstraZeneca, Bristol Myers Squibb, Ely Lilly, Merck, Merck Sharp & Dohme, Novartis, Pamgene, Pfizer, and Roche, outside the scope of this manuscript. WHvH reports on a non-restricted grant from Novartis. GSS reports institutional research support from AstraZeneca, Merck, Novartis, and Roche outside the scope of this manuscript. All other authors have declared no conflicts of interest.

Cite this